longbridgelongbridge
  • Platform Features
    Features
    Investment ProductsPrivate Wealth ManagementTrading ToolsMarket Data ServicesAnalysis ToolsNews ServicesFor Developers
    Account Types
    For IndividualsFor Institutions
  • Café
longbridge
© 2026 Longbridge|Terms of ServicePrivacy Policy

Arcturus Therapeutics

ARCT

16.0305.32% ( -0.900 )
Closed: Sep 18, 16:00:00 (EDT)
Start trading
OverviewOverviewOptionsOptionsNewsNewsPostsPostsFinancialsFinancialsForecastForecastValuationValuationShareholdersShareholdersProfileProfile
LongbridgeAI
  • Arcturus to present Phase 2 ARCT-810 clinical data in OTC deficiency on Sept. 23

    PUBT·1 day ago, 01:01 PM
    ARCT-5.32%
  • The Undercurrents of Infrastructure and Software: Key Moves for Q4

    Global Report·Sep 15 at 09:18 AM
    RSG-0.39%FFIV-0.60%
  • National Beverage Posts Downbeat Q1 Results, Joins Zumiez, Adobe And Other Big Stocks Moving Lower In Friday’s Pre-Market Session

    benzinga_article·Sep 11 at 12:04 PM
    - National Beverage Corp reported lower-than-expected first-quarter earnings of 50 cents per share and sales of $330.662 million, causing its shares to dip 3.5% to $29.83 in pre-market trading. - Several other prominent stocks also experienced declines during Friday's pre-market session following recent financial reports. - Zumiez Inc fell 15.7% to $14.07 after releasing disappointing second-quarter results, while Adobe Inc dropped 3.1% to $241.01 despite posting better-than-expected third-quarter fiscal 2026 figures.
    BLZE-4.57%ARCT-5.32%
  • Citi Keeps Their Hold Rating on Arcturus Therapeutics (ARCT)

    Tip Ranks·Sep 10 at 11:05 AM
    ARCT-5.32%
  • Corporate Realignment Signals Build: From Media Mergers to Industrial Divestitures

    Global Report·Sep 8 at 09:19 AM
    PSKY-3.86%TMO-1.04%
  • Arcturus Therapeutics to Participate in Upcoming Investor Conferences | ARCT Stock News

    StockTitan·Aug 31 at 12:01 PM
    ARCT-5.32%
  • Weekly Recap | ARCT.US +12.94%, most brokers rate it buy

    Weekly Review·Aug 29 at 05:13 AM
    ARCT-5.32%
  • Roth MKM Sticks to Their Buy Rating for Arcturus Therapeutics (ARCT)

    Tip Ranks·Aug 26 at 11:55 AM
    ARCT-5.32%
  • Niche U.S. Equities Face Strategic Shifts From Aviation Buyouts to Biotech Pipeline Advances

    Global Report·Aug 25 at 11:33 AM
    FLY-3.45%ARCT-5.32%
  • Arcturus Therapeutics to Present ARCT-810 Data on OTC Deficiency at 2026 Symposium

    TradingView·Aug 25 at 10:13 AM
    ARCT-5.32%
  • Mixed Signals Emerge Across Specialized Assets and Energy Markets

    Global Report·Aug 25 at 09:21 AM
    LEGN+0.17%AVEX-2.88%